Supplemental digital content 1: Incidence of Low White Cell Counts and High-dose Corticosteroid Exposure Prior to the Diagnosis of Tuberculosis in Patients with and without Culture-Confirmed Tuberculosis

|  |  |  |  |
| --- | --- | --- | --- |
| Event | Patients with culture-confirmed Tuberculosis  (Total person-years = 11) | Patients with no culture-confirmed Tuberculosis  (Total person-years = 427) | p-value8 |
| Incidence1 of cycles of high-dose corticosteroids prior to TB2 diagnosis (95% CI3); n4 | 472.7 (353.1-619.9); n=52 | 31.4 (26.3-37.2); n=134 | <0.001 |
| Incidence of SE5 with prolonged neutropenia prior to TB diagnosis (95% CI); n | 445.5 (329.5-588.9); n=49 | 37 (31.5-43.2); n=158 | <0.001 |
| Incidence of SE with profound6 neutropenia prior to TB diagnosis (95% CI); n | 409.1 (298.4-547.4); n=45 | 33.7 (28.4-39.7); n=144 | <0.001 |
| Incidence of SE prolonged 7 lymphopenia prior to TB diagnosis (95% CI); n | 481.8 (360.9-630.2); n=53 | 42.9 (36.9-49.5); n=183 | <0.001 |
| Incidence of SE with profound lymphopenia prior to TB diagnosis (95% CI); n | 372.7 (267.5-505.6); n=41 | 29.3 (24.4-34.9); n=125 | <0.001 |
| Incidence of SE with prolonged monocytopenia prior to TB diagnosis (95% CI); n | 636.4 (496.1-804); n=70 | 49.9 (43.4-57.1); n=213 | <0.001 |
| Incidence of SE with profound monocytopenia prior to TB diagnosis (95% CI); n | 545.5 (416.2-702.1); n=60 | 45.7 (39.5-52.5); n=195 | <0.001 |

Incidence1 = incidence per 100 child years where incidence is defined as the number of events divided by the total person-years multipled by 100; TB2 =Tuberculosis; 3 CI = Confidence interval; 4 N =Number of events; SE 5 =Septic episode; 6Profound neutropenia, lymphopenia, and monocytopenia = absolute cell counts < 100 cells/µL; 7Prolonged neutropenia, lymphopenia, and monocytopenia = absolute counts of <1000 cells/µL for ≥7 days; 8p-value when comparing children who developed Tuberculosis to those that did not.

Supplemental digital content 2: Summary of Deaths in Children with Tuberculosis

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Age at Cancer Diagnosis (months) | Diagnosis | RVD 8 status | Sex | Culture-confirmed TB11 | Other Infections |
| 155 | NHL1 | Positive | M 9 | No | **Blood**: MRSA 12, **CSF** 13 : MRSA, **NPA** 14: HMPV 15 |
| 192 | ALL2 | Negative | F 10 | No | Blood: VRE 16 and ESBL 17 *Escherichia coli*, **NPA**: CV 18HUK1 |
| 119 | KS 3 | Positive | M | Yes | **NPA:** HRV 19  and **Adenovirus** |
| 55 | ALL | Negative | M | No | **Blood**: *Micrococcus* , **NPA**: HPyV 20 Ki and Influenza A |
| 20 | AML4 | Negative | M | No | **Blood**: *Escherichia coli*, **NPA**: Influenza A, **Urine**: *Escherichia coli* |
| 121 | NHL | Negative | M | No | **Blood**: CNS |
| 76 | NHL | Positive | F | Yes | **NPA**: Influenza A, CVOC43, CVNL63 and HRV |
| 14 | ALL | Negative | F | No | **Urine**: *Enterococcus faecalis* |
| 123 | NHL | Positive | F | No | **Blood**: *Acinetobacter baumanni* and *Stenotrophia maltophilia* |
| 122 | ALL | Negative | M | No | **Blood**: *Klebsiella pneumoniae* and *Bacillus*, **NPA**: CVOC43 and CVHUK1, **Abscess**: *Staphylococcus hominis* |
| 20 | ALL | Negative | F | Yes | **Blood**: CNS21 , **Urine**: *Escherichia coli* |
| 80 | AML | Negative | F | No | **Blood**: CNS, PR22 *Acinetobacter baumanni*, **CSF**: VRE, **Urine**: ESBL *Escherichia coli* |
| 112 | ALL | Negative | F | No | **Blood**: CNS, PR *Acinetobacter baumanni* and VRE, **NPA**: CVNL63, **Urine**: ESBL *Escherichia coli* |
| 148 | NHL | Positive | M | No | **Blood**: CNS |
| KS | AML | Negative | M | No | **Blood**: CNS, **NPA**: HRV |
| 152 | ALL | Negative | F | No | **Blood**: *Acinetobacter lwoffii* |
| 122 | OS5 | Negative | M | No | **CSF**: *Candida albicans* |
| 41 | WT6 | Negative | M | No | **Blood**: CNS |
| 166 | NHL | Positive | M | No | NPA: HMPV |
| 90 | ALL | Negative | F | Yes | **Blood**: ESBL *Klebsiella pneumoniae*, **NPA**: CVNL63 and HPyVKi |
| 164 | ALL | Negative | M | Yes | **Blood**: ESBL *Klebsiella pneumoniae*, **Urine**: *Pseudomonas aeruginosa* |
| 144 | ALL | Negative | F | No | **Blood**: ESBL *Klebsiella pneumoniae*, **Urine**: *Pseudomonas aeruginosa* |
| 18 | NHL | Positive | M | Yes | **NPA**: CVNL63 and HRV, **Urine**: ESBL *Escherichia coli* |
| 61 | ACC7 | Negative | F | Yes | **Blood**: CNS |
| 36 | ALL | Negative | F | No | **Blood**: *Candida albicans*, **NPA**: CVOC43, **Urine**: ESBL *Klebsiella pneumoniae* |
| 50 | NHL | Positive | M | No | **Blood**: CNS, **NPA**: HRV, **Urine**: *Escherichia coli* |

NHL1 = Non-Hodgkin lymphoma; ALL2 =Acute lymphoblastic leukaemia; KS3 =Kaposi sarcoma; AML4 =Acute myeloid leukaemia; OS5 =Osteogenic sarcoma;WT6 =Wilm’s tumour; ACC7 =Adrenocortical carcinoma; RVD8 =Retroviral disease; M9 =male; F10 =female; TB11 =tuberculosis; MRSA12 = methicillin-resistant *Staphylococcus aureus*; CSF12 =cerebrospinal fluid; NPA14 =nasopharyngeal aspirate; HMPV15 =human Metapneumovirus; VRE16 =vancomycin-resistant *Enterococcus;* ESBL17 =extended-spectrumβ lactamase producer; CV18 =coronavirus; HRV19 =human Rhinovirus; HPyV20 =human Polyomavirus; CNS21 =coagulase-negative *Staphylococcus*; PR22 =pan-resistant.